Companies ask FDA for regulation, improvement of data collection from digital health devices
The FDA should consider regulating how data gathered from digital health devices like continuous glucose monitors and sensors are incorporated into clinical-trial submissions, according to several comment letters from multiple advocate and industry organizations.
At least five organizations have submitted public comments on the FDA’s proposal examining how best to use digital health technologies (DHTs) in drug and biologic development, particularly in decentralized clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.